chr4:75230860:> Detail (hg19) (EREG)
Information
Genome
| Assembly | Position |
|---|---|
| hg19 | chr4:75,230,860-75,254,468 |
| hg38 | chr4:74,365,143-74,388,751 |
HGVS
| Type | Transcript | Protein |
|---|---|---|
Summary
MGeND
| Clinical significance | |
| Variant entry | |
| GWAS entry | |
| Disease area statistics | Show details |
Frequency
[No Data.]
Prediction
[No Data.]
ClinVar
| Clinical Significance | |
| Review star | [No Data.] |
| Show details | |
Links
Disease area statistics
[No Data.]
MGeND
[No Data.]
ClinVar
[No Data.]
CIViC
| Disease | Drug | EL | ET | ED | CS | VO | TR | Pubmed | Links |
|---|---|---|---|---|---|---|---|---|---|
| colorectal cancer | Panitumumab | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
4 | 26867820 | Detail |
| lung adenocarcinoma | E |
Prognostic
|
Supports
|
Poor Outcome |
N/A
|
2 | 26894620 | Detail | |
| colorectal cancer | Cetuximab | B |
Predictive
|
Supports
|
Sensitivity/Response |
N/A
|
3 | 23374602 | Detail |
DisGeNET
[No Data.]
Annotation
Annotations
| Descrption | Source | Links |
|---|---|---|
| Prospectively planned retrospective biomarker study in archived tumor tissue from 323 patients from ... | CIViC Evidence | Detail |
| Study reporting an in-vivo two-stage initiation/promotion model, testing the hypothesis that Ereg de... | CIViC Evidence | Detail |
| 226 cetuximab-treated patients with CRC were analyzed for mRNA expression of EGFR and its ligands. F... | CIViC Evidence | Detail |
Overlapped Transcript Coordinates
| Gene | Transcript ID | Exon Number | Chromosome | Start | Stop | Type | Amino Mutation | Transcript Position | Links |
|---|
Overlapped Transcript
| Gene | Transcript ID | Chromosome | Start | Stop | Links |
|---|
- Gene
- -
- Genome
- hg19
- Position
- chr4:75,230,860-75,254,468
- Variant Type
- snv
- Variant (CIViC) (CIViC Variant)
- EXPRESSION
- Transcript 1 (CIViC Variant)
- ENST00000244869.2
- Variant URL (CIViC Variant)
- https://civic.genome.wustl.edu/links/variants/318
Genome browser